DepoMed, Inc. (NASDAQ:DEPO)

CAPS Rating: 4 out of 5

A specialty pharmaceutical company focused on the development and commercialization of differentiated products that address growing markets and are based on proprietary oral drug delivery technologies.


Player Avatar ssbb123 (28.15) Submitted: 2/22/2010 3:16:36 PM : Underperform Start Price: $2.46 DEPO Score: -474.77

"Cancer risk" can't see this being a good investment for the next few months at least.

Featured Broker Partners